XML 22 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation
9 Months Ended
Jun. 26, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Note 4.Stock-Based Compensation

 

The Company has traditionally maintained incentive compensation plans that include provision for the issuance of equity-based awards. The Company established the 2008 Omnibus Equity Incentive Compensation Plan in 2008 (the “2008 Plan”). The Company has issued awards under the 2008 Plan. Subsequently, the 2008 Plan expired in 2018 and the Company established a new plan, the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”) during the third fiscal quarter of 2018, pursuant to shareholder approval.

 

Stock-based compensation is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the grant). The company recognizes the impact of forfeitures as forfeitures occur.

 

Our net loss for the three quarters ended June 26, 2018 and June 27, 2017 includes $303,000 and $609,000, respectively, of compensation costs related to our stock-based compensation arrangements.

 

Stock Option awards

 

The Company measures the compensation cost associated with stock option awards by estimating the fair value of the award as of the grant date using the Black-Scholes pricing model. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s stock options and stock awards granted during the first three fiscal quarters ended June 26, 2018. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by the employees who receive equity awards.

 

During the three quarters ended June 26, 2018, the Company granted a total of 18,274 incentive stock options, from available shares under its 2008 Plan, as amended, with exercise prices between $2.70 and $2.73 and per-share weighted average fair values between $1.65 and $1.95. The Company did not issue any stock options under the 2018 plan during the three quarters ended June 26, 2018.

 

During the three quarters ended June 27, 2017, the Company granted a total of 151,834 incentive stock options, from available shares under its 2008 Plan, as amended, with exercise prices between $3.05 and $3.15 and per-share weighted average fair values between $2.17 and $2.30.

 

In addition to the exercise and grant date prices of the stock option awards, certain weighted average assumptions that were used to estimate the fair value of stock option grants are listed in the following table:

 

    Fiscal 2018
Incentive and
Non-Statutory Stock Options
 

Fiscal 2017

Incentive and
Non-Statutory Stock Options

Expected term (years)   7.5   6.5 to 7.5
Expected volatility   75.33% to 75.67%   75.41% to 80.70%
Risk-free interest rate   2.17% to 2.35%   1.49% to 2.40%
Expected dividends   0   0

 

We estimate expected volatility based on historical weekly price changes of our common stock for a period equal to the current expected term of the options. The risk-free interest rate is based on the United States treasury yields in effect at the time of grant corresponding with the expected term of the options. The expected option term is the number of years we estimate that options will be outstanding prior to exercise considering vesting schedules and our historical exercise patterns.

 

The following table summarizes stock option activity for the three quarters ended June 26, 2018 under all plans:

 

   Shares   Weighted
Average
Exercise Price
   Weighted Avg.
Remaining
Contractual Life (Yrs.)
Outstanding-at beginning of year   681,922   $4.25    
Options granted   18,274   $2.71    
Options exercised   0         
Forfeited   (43,807)  $4.49    
Expired   (2,933)  $17.25    
Outstanding June 26, 2018   653,456   $4.14   6.0
Exercisable June 26, 2018   508,483   $4.29   5.3

 

As of June 26, 2018, the aggregate intrinsic value of the outstanding and exercisable options was $391,000 and $348,000, respectively. Only options whose exercise price is below the current market price of the underlying stock are included in the intrinsic value calculation.

 

As of June 26, 2018, the total remaining unrecognized compensation cost related to non-vested stock options was $318,000 and is expected to be recognized over a weighted average period of approximately 1.8 years.

 

There were no stock options exercised during the three quarters ended June 26, 2018 and June 27, 2017.

 

Restricted Stock Units

 

During the three quarters ended June 26, 2018, the Company granted a total of 37,037 restricted stock units from available shares under its 2008 Plan, as amended. The shares were issued with a grant date fair market value of $2.70 which is equal to the closing price of the stock on the date of the grant. The restricted stock units vest over three years following the grant date. The Company did not issue any restricted stock units under the 2018 plan during the three quarters ended June 26, 2018.

 

During the three quarters ended June 27, 2017, the Company granted a total of 103,440 shares of restricted stock from available shares under its 2008 Plan, as amended. The shares were issued with grant date fair market values of $3.15 and $3.20 which is equal to the closing price of the stock on the date of the grants. The restricted stock grants vest between three months and three years following the grant date.

 

A summary of the status of non-vested restricted stock as of June 26, 2018 is presented below.

 

   Shares   Grant Date Fair
Value Per Share
Non-vested shares at beginning of year   115,039   $3.15 to $8.60
Granted   37,037   $2.70
Forfeited   (16,699)  $3.15 to $4.18
Vested   (41,037)  $3.15 to $4.18
Non-vested shares at June 26, 2018   94,340   $2.70 to $8.60

 

As of June 26, 2018, there was $186,000 of total unrecognized compensation cost related to non-vested restricted stock. This cost is expected to be recognized over a weighted average period of approximately 1.3 years.